Translational advances of exosomes in neurodegeneration towards precision healthcare: From biomarkers to therapeutic frontiers

Exosomes are nanoscale extracellular vesicles (EVs) that mediate intercellular communication and carry proteins, lipids, mRNAs, and non-coding RNAs reflective of their parental cells. Their biogenesis, molecular composition, and ability to traverse physiological barriers, including the blood-brain barrier, position exosomes as powerful candidates for biomarker development and therapeutic delivery in neurodegenerative diseases (NDDs). In Alzheimer's disease, Parkinson's disease, multiple sclerosis, and prion disorders, exosomes not only mirror pathological processes but actively participate in the propagation of misfolded proteins and neuroinflammatory signals through cell-type-specific vesicle subpopulations. This review synthesises current advances in exosome biology, cargo sorting, release mechanisms, and pathophysiological roles in the central nervous system, with emphasis on how neuron-, astrocyte-, and microglia-derived exosomes diverge in their cargo profiles and functional consequences across diseases. We highlight disease-specific exosomal signatures, including amyloid-β (Aβ), tau, α-synuclein, myelin proteins, prion proteins (PrP) and regulatory microRNAs. We evaluate emerging technologies such as microfluidic isolation, single-vesicle analysis, and multi-omics profiling that are accelerating biomarker discovery, and review exosome-based therapeutic strategies, including native stem cell-derived exosomes and surface-engineered vesicles loaded with neuroprotective miRNAs, small molecules, and gene-editing cargo. We address critical unmet challenges in translating these approaches to the clinic, including scalable and standardised production, incomplete pharmacokinetic /pharmacodynamic characterisation in preclinical models, immunogenicity and off-target safety concerns, and the absence of specific regulatory guidance for EV drug products. Together, these insights highlight the transformative potential of exosomes as both precision diagnostic tools and disease-modifying therapeutic platforms for NDDs.

Authors

Institutions

Publication Details

Journal
Biomedicine & Pharmacotherapy
Published
2026-04-16
DOI
https://doi.org/10.1016/j.biopha.2026.119297
Primary Topic
Extracellular vesicles in disease
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Translational advances of exosomes in neurodegeneration towards precision healthcare: From biomarkers to therapeutic frontiers

Jianxun Song, Bharmjeet Singh, Anik Karan, Devangna Paul et al.
Biomedicine & Pharmacotherapy
Extracellular vesicles in disease
article

Translational advances of exosomes in neurodegeneration towards precision healthcare: From biomarkers to therapeutic frontiers

Jianxun Song, Bharmjeet Singh, Anik Karan, Devangna Paul, A. C. Mishra, Tiya Verma, Rugved Rane, Benny S. Song, Rashi Sharma
article en

Abstract

Exosomes are nanoscale extracellular vesicles (EVs) that mediate intercellular communication and carry proteins, lipids, mRNAs, and non-coding RNAs reflective of their parental cells. Their biogenesis, molecular composition, and ability to traverse physiological barriers, including the blood-brain barrier, position exosomes as powerful candidates for biomarker development and therapeutic delivery in neurodegenerative diseases (NDDs). In Alzheimer's disease, Parkinson's disease, multiple sclerosis, and prion disorders, exosomes not only mirror pathological processes but actively participate in the propagation of misfolded proteins and neuroinflammatory signals through cell-type-specific vesicle subpopulations. This review synthesises current advances in exosome biology, cargo sorting, release mechanisms, and pathophysiological roles in the central nervous system, with emphasis on how neuron-, astrocyte-, and microglia-derived exosomes diverge in their cargo profiles and functional consequences across diseases. We highlight disease-specific exosomal signatures, including amyloid-β (Aβ), tau, α-synuclein, myelin proteins, prion proteins (PrP) and regulatory microRNAs. We evaluate emerging technologies such as microfluidic isolation, single-vesicle analysis, and multi-omics profiling that are accelerating biomarker discovery, and review exosome-based therapeutic strategies, including native stem cell-derived exosomes and surface-engineered vesicles loaded with neuroprotective miRNAs, small molecules, and gene-editing cargo. We address critical unmet challenges in translating these approaches to the clinic, including scalable and standardised production, incomplete pharmacokinetic /pharmacodynamic characterisation in preclinical models, immunogenicity and off-target safety concerns, and the absence of specific regulatory guidance for EV drug products. Together, these insights highlight the transformative potential of exosomes as both precision diagnostic tools and disease-modifying therapeutic platforms for NDDs.

Biomedicine & PharmacotherapyVol. 199
Texas A&M Health Science Center (US), University of Kansas (US), University of Freiburg (DE), Symbiosis International University (IN), Government of Uttar Pradesh (IN), Texas A&M Health Science Center (US), International Centre for Genetic Engineering and Biotechnology (IN), Delhi Technological University (IN), Texas A&M University (US)
Foundation for the National Institutes of Health, National Institutes of Health
Openalex Percentile: Top 20%
Extracellular vesicles in disease
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.